Desmoplastic Small Round Cell Tumor Treatment Market - Global Industry Insights,Posted by Pareesh on June 18th, 2018 Desmoplastic Small Round Cell Tumor (DSRCT) refers to a rare kind of aggressive soft tissue cancer that usually begins at abdomen and hematogenously disseminates to the liver. According to the National Institute of Health, the disease primarily affects children and young adults, as is more prevalent in males than that in females. According to the Health Program of European Union, desmoplastic small round cell tumor is extremely rare and only a few hundred cases have been reported worldwide till 2011 since its first description in 1989. Click To Continue Reading on Desmoplastic Small Round Cell Tumor Treatment Market Moreover, according to National Cancer Intelligent Network, Public Health England, only three incidence cases of DSRC were reported between 2010 and 2013 in England. The Desmoplastic Small Round Cell tumor is formed by small, round cancer cells that are surrounded by scar-like tissue that are found in the peritoneum lining inside of the abdomen and pelvis. The tumor cells also undergo a characteristic genetic change that involves translocation among chromosomes 11 and 22 that differentiates the tumor from various other cancerous tumors. Increasing incidence of genetic disorders and cancer is one of the major factors responsible for growth of the global desmoplastic small round cell tumor treatment market. According to a report published by Genetics Education Center, University of Kansas Medical Center 2012, 12% of the hospital admissions in the U.S. accounted for treatment of genetic causes in 2013. Moreover, according to the American Cancer Society 2017, the cancer occurring in stomach, small intestine, and gastrointestinal cavity are one of the most common of the rare cancer of the digestive systems. According to the Cancer Research UK 2016, rare cancers affects around 2 in 100,000 people. Additionally, increasing research and development to improve conditions of the patients suffering with rare cancers is also responsible to augment the market growth. Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/1569 Key Vendors: Glentham Lifesciences Ltd., Novartis AG, NantCell, Inc., Daiichi Sankyo, Inc., F. Hoffmann-L-Roche, and others. About Coherent Market Insights: Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity. Mr. Shah Like it? Share it! More by this author |